Investment will support development of ALS drug “enhancer”
New investment builds on recent breakthroughs with availability of three new neuromuscular disease drugs
Washington, D.C., March 6, 2017 – A coalition of eleven nonpartisan patient groups today laid out a joint set of goals they want Congress to focus on as it considers changes to the Affordable Care Act.
The program now in its 35th year has raised millions to support families with muscular dystrophy, ALS and related life-threatening diseases.
Muscular Dystrophy Association National Office
222 S. Riverside Plaza, Suite 1500
Chicago, Illinois 60606
800-572-1717 | ResourceCenter@mdausa.org
The Muscular Dystrophy Association (MDA) is a qualified 501(c)(3) tax-exempt organization.
©2018, Muscular Dystrophy Association Inc. All rights reserved.